0001641172-25-003977.txt : 20250414 0001641172-25-003977.hdr.sgml : 20250414 20250414094804 ACCESSION NUMBER: 0001641172-25-003977 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20250414 DATE AS OF CHANGE: 20250414 EFFECTIVENESS DATE: 20250414 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ensysce Biosciences, Inc. CENTRAL INDEX KEY: 0001716947 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 822755287 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-543546 FILM NUMBER: 25834415 BUSINESS ADDRESS: STREET 1: 7946 IVANHOE AVENUE STREET 2: SUITE 201 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 263-4196 MAIL ADDRESS: STREET 1: 7946 IVANHOE AVENUE STREET 2: SUITE 201 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: Leisure Acquisition Corp. DATE OF NAME CHANGE: 20170913 D 1 primary_doc.xml X0708 D LIVE 0001716947 Ensysce Biosciences, Inc. 7946 IVANHOE AVE, SUITE 201 LA JOLLA CA CALIFORNIA 92037 (858) 263-4196 DELAWARE None Leisure Acquisition Corp. Corporation true D Lynn Kirkpatrick 7946 Ivanhoe Ave, Suite 201 La Jolla CA CALIFORNIA 92037 Executive Officer Director Bob Gower 7946 Ivanhoe Ave, Suite 201 La Jolla CA CALIFORNIA 92037 Director William Chang 7946 Ivanhoe Ave, Suite 201 La Jolla CA CALIFORNIA 92037 Director Andrew Benton 7946 Ivanhoe Ave, Suite 201 La Jolla CA CALIFORNIA 92037 Director Steve Martin 7946 Ivanhoe Ave, Suite 201 La Jolla CA CALIFORNIA 92037 Director Adam Levin 7946 Ivanhoe Ave, Suite 201 La Jolla CA CALIFORNIA 92037 Director Curtis Rosebraugh 7946 Ivanhoe Ave, Suite 201 La Jolla CA CALIFORNIA 92037 Director David Humphrey 7946 Ivanhoe Ave, Suite 201 La Jolla CA CALIFORNIA 92037 Executive Officer Lee Rauch 7946 Ivanhoe Ave, Suite 201 La Jolla CA CALIFORNIA 92037 Director Other Health Care Decline to Disclose 06b false 2025-03-31 false true false 0 H.C. Wainwright & Co., LLC 000000375 None None 430 PARK AVENUE NEW YORK NY NEW YORK 10022 NY NEW YORK false 1100000 1100000 0 false 8 142950 0 Consists of amounts received in a concurrent registered offering of $77,000 (commission), $50,000 (expense), $15,950 (clearing fee) and warrants to purchase 22,063 shares of common stock. 0 false Ensysce Biosciences, Inc. /s/ Lynn Kirkpatrick Dr. Lynn Kirkpatrick President and CEO 2025-04-14